Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol

Journal of Veterinary Internal Medicine

Volumn 21, Issue 6, 2007, Pages 1332-1339

  Vaughan, Andrew ^a,c   Johnson, Jeffrey L ^b   Williams, Laurel E ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c Las Vegas Veterinary Referral Center   (United States)

Author keywords

Dose escalation; Fractional dose intensity; Lymphosarcoma; Neutropenia; Summation dose intensity

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; DOSE RESPONSE; FEMALE; LYMPHOMA; MALE; MULTIMODALITY CANCER THERAPY; RADIOTHERAPY; REMISSION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMIBODY IRRADIATION; LYMPHOMA; MALE; REMISSION INDUCTION;

ANIMALIA; CANIS FAMILIARIS;

EID: 37349092699     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/06-197.1     Document Type: Article

References (54)

1. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy for node-positive breast cancer. J Clin Oncol 2003;21:1431-1439.
2. Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: A study of the cancer and leukemia group B. J Clin Oncol 2003;21:5-15.
3. Cushing B, Giller R, Cullen JW, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: A pediatric intergroup study - Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol 2004;22:2691-2700.
4. Breitfeld PP, Lyden E, Raney RB, et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: A report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol 2001;23:225-233.
5. Keller ET, MacEwen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993;7:289-295.
6. Zemann BI, Moore AS, Rand WM, et al. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. J Vet Intern Med 1998;12:465-170.
7. Chu E. Principles of medical oncology. In Devita VT Jr, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Philadelphia, PA: Lippincott; 2005.295-306.
8. Frei E, Elias A, Wheeler C, et al. The relationship between high-dose treatment and combination chemotherapy: The concept of summation dose intensity. Clin Cancer Res 1998;4:2027-2037.
9. Rassnick KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 1999;13:601-605.
10. Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor - 41 cases (1992-1997). J Vet Intern Med 1999;13:491-497.
11. Berg J, Weinstein MJ, Schelling SH, et al. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987-1990). J Am Vet Med Assoc 1992;200:2005-2008.
12. Berg J, Weinstein MJ, Springfield DS, et al. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995;206:1555-1560.
13. Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996;10:76-81.
14. Ogilvie GK, Powers BE, Mallinckrodt CH, et al. Surgery and doxorubicin in dogs with hemangiosarcoma. J Vet Intern Med 1996;10:379-384.
15. Henry CJ, McCaw DL, Turnquist SE, et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin Cancer Res 2003;9:906-911.
16. Novosad CA, Bergman PJ, O'Brien MG, et al. Retrospective evaluation of adjunctive doxorubicin for the treatment of feline mammary gland adenocarcinoma: 67 cases. J Am Anim Hosp Assoc 2006;42:110-120.
17. Hammer AS, Couto CG, Filppi J, et al. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. J Vet Intern Med 1991;5:160-166.
18. Sorenmo KU, Jeglum KA, Helfand SC. Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. J Vet Intern Med 1993;7:370-376.
19. Berg J, Gebhardt MC, Rand WM. Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 1997;79:1343-1350.
20. DeRegis CJ, Moore AS, Rand WM, et al. Cisplatin and doxorubicin toxicosis in dogs with osteosarcoma. J Vet Intern Med 2003;17:668-673.
21. Bailey D, Erb H, Williams L, et al. Carboplatin and doxorubicin combination chemotherapy for the treatment of appendicular osteosarcoma in the dog. J Vet Intern Med 2003;17:199-205.
22. Moore AS, Cotter SM, Rand WM, et al. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. J Vet Intern Med 2001;15:348-354.
23. Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704-709.
24. Brick JO, Roenigk WJ, Wilson GP. Chemotherapy of malignant lymphoma in dogs and cats. J Am Vet Med Assoc 1968;153:47-52.
25. Postorino NC, Susaneck SJ, Withrow SJ, et al. Single agent therapy with adriamycin for canine lymphosarcoma. J Am Anim Hosp Assoc 1989;25:221-225.
26. MacDonald VS, Thamm DH, Kurzman ID, et al. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? J Vet Intern Med 2005;19:732-736.
27. Bonadonna G, Callagusa R. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:10-15.
28. Lagarde P, Bonichon F, Eghbali H, et al. Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease. Br J Cancer 1989;59:645-649.
29. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997;24(4Suppl 10):S10-3-S10-10.
30. Hryniuk W. The importance of dose intensity in outcome of chemotherapy. In Devita VT Jr, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia, PA: Lippincott; 1988.121-141.
31. Longo DL, Duffey PL, DeVita VT Jr, et al. The calculation of actual or received dose intensity: A comparison of published methods. J Clin Oncol 1991;9:2042-2051.
32. Apelbaum R, Faraggi D, Ben-Arie Y, et al. Survival of diffuse large cell lymphoma.A multivariate analysis including dose intensity variables. Cancer 1990;66:1124-1129.
33. Portlock CS, Qin J, Schaindlin p, et al. The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: A sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. Ann Oncol 2004;15:1495-1503.
34. Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: Optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005;130:691-699.
35. Kaufman D, Longo DL. Hodgkin's disease. Crit Rev Oncol Hematol 1992;13:135-187.
36. Chabner BA. Clinical strategies for cancer treatment: The role of drugs. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy. Philadelphia, PA: Lippincott; 2006.10-11.
37. Frimberger AE, Moore AS, Rassnick KM, et al. A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma. J Vet Intern Med 2006;20:355-364.
38. MacEwen EG, Brown NO, Patnaik AK, et al. Cyclic combination chemotherapy of canine lymphoma. J Am Vet Med Assoc 1981;178:1178-1181.
39. Madewell BR. Chemotherapy for canine lymphosarcoma. Am J Vet Res 1975;36:1525-1528.
40. Cotter SM. Treatment of lymphoma and leukemia with cyclophosphamide, vincristine and prednisone: I. Treatment of dogs. J Am Anim Hosp Assoc 1983;19:159-165.
41. Williams LE, Johnson JL, Hauck ML, et al. Chemotherapy followed by half-body radiation therapy for canine lymphoma. J Vet Intern Med 2004;18:703-709.
42. Owen L. TNM Classification of Tumors in Domestic Animals. Geneva: World Health Organiztion 1980;46-47.
43. Veterinary Co-operative Oncology Group, Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological anti-neoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194-213.
44. Collett D. Modelling Survival Data in Medical Research, 2nd ed. London: Chapman & Hall; 2003.
45. Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall; 1991.
46. Neff MW, Robertson KR, Wong AK, et al. Breed distribution and history of canine mdr1-1Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc Natl Acad Sci U S A 2004;101:11725-11730.
47. Ratain MJ, Miller AA, McLeod HL, et al. The cancer and leukemia group B pharmacology and experimental therapeutics committee: A historical perspective. Clin Cancer Res 2006;12: 3612s-3616s.
48. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: A model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006;6:117-129.
49. Mealey KL, Bentjen SA, Waiting DK. Frequency of the mutant MDR1 allele associated with ivermectin sensitivity in a sample population of Collies from the northwestern United States. Am J Vet Res 2002;63:479-481.
50. Mealey KL, Northrup NC, Bentjen SA. Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J Am Vet Med Assoc 2003;223:1453-1455.
51. Chun R, Garrett LD, Vail DM. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2000;14:120-124.
52. Charney SC, Bergman PJ, Hohenhaus AE, et al. Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990-1996). J Am Vet Med Assoc 2003;222:1388-1393.
53. Rassnick KM, Frimberger KE, Wood CA, et al. Evaluation of ifosfamide for treatment of various canine neoplasms. J Vet Intern Med 2000;14:271-276.
54. Salavaggione OE, Kidd L, Prondzinski JL, et al. Canine red blood cell thiopurine S-methyltransferase: Companion animal pharmacogenetics. Pharmacogenetics 2002;12:713-724.